Illumina Inc.

224.88+10.08+4.69%Vol 527.38K1Y Perf -57.58%
Aug 10th, 2022 13:41 DELAYED
BID224.76 ASK225.00
Open221.50 Previous Close214.80
Pre-Market218.82 After-Market-
 4.02 1.87%  - -
Target Price
328.70 
Analyst Rating
Hold 2.56
Potential %
46.38 
Finscreener Ranking
★★★+     51.04
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     50.59
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     66.87
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
14.59 
Earnings Rating
Strong Sell
Market Cap35.33B 
Earnings Date
11th Aug 2022
Alpha-0.00 Standard Deviation0.10
Beta1.10 

Today's Price Range

220.36226.63

52W Range

173.45526.00

5 Year PE Ratio Range

29.20124.90

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-3.72%
1 Month
9.01%
3 Months
-2.22%
6 Months
-40.01%
1 Year
-57.58%
3 Years
-26.94%
5 Years
10.35%
10 Years
392.66%

TickerPriceChg.Chg.%
ILMN224.8810.07504.69
AAPL168.113.18501.93
GOOG120.863.36002.86
MSFT288.526.22002.20
XOM91.641.05001.16
WFC44.471.07002.47
JNJ169.85-0.3300-0.19
FB196.640.99000.51
GE77.522.59003.46
JPM118.262.88002.50
 
ProfitabilityValueIndustryS&P 500US Markets
68.80
19.40
25.70
27.00
14.53
RevenueValueIndustryS&P 500US Markets
3.53B
22.47
8.95
10.93
Earnings HistoryEstimateReportedSurprise %
Q01 20220.871.0722.99
Q04 20210.500.7550.00
Q03 20211.241.4516.94
Q02 20211.361.8737.50
Q01 20211.361.8938.97
Q04 20201.211.220.83
Q03 20200.771.0232.47
Q02 20200.720.62-13.89
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.63-35.71Negative
9/2022 QR1.10-1.79Negative
12/2022 FY4.09-1.21Negative
12/2023 FY5.341.14Positive
Next Report Date11th Aug 2022
Estimated EPS Next Report0.63
Estimates Count7
EPS Growth Next 5 Years %31.20
Volume Overview
Volume527.38K
Shares Outstanding157.10K
Shares Float136.43M
Trades Count15.48K
Dollar Volume118.19M
Avg. Volume1.09M
Avg. Weekly Volume884.11K
Avg. Monthly Volume1.06M
Avg. Quarterly Volume1.34M

Illumina Inc. (NASDAQ: ILMN) stock closed at 214.8 per share at the end of the most recent trading day (a -3.67% change compared to the prior day closing price) with a volume of 802.91K shares and market capitalization of 35.33B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 7850 people. Illumina Inc. CEO is Francis A. DeSouza.

The one-year performance of Illumina Inc. stock is -57.58%, while year-to-date (YTD) performance is -43.54%. ILMN stock has a five-year performance of 10.35%. Its 52-week range is between 173.45 and 526, which gives ILMN stock a 52-week price range ratio of 14.59%

Illumina Inc. currently has a PE ratio of 41.40, a price-to-book (PB) ratio of 2.73, a price-to-sale (PS) ratio of 8.34, a price to cashflow ratio of 67.00, a PEG ratio of 2.32, a ROA of 5.96%, a ROC of 6.96% and a ROE of 9.02%. The company’s profit margin is 14.53%, its EBITDA margin is 25.70%, and its revenue ttm is $3.53 Billion , which makes it $22.47 revenue per share.

Of the last four earnings reports from Illumina Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.63 for the next earnings report. Illumina Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Illumina Inc. is Hold (2.56), with a target price of $328.7, which is +46.38% compared to the current price. The earnings rating for Illumina Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Illumina Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Illumina Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.60, ATR14 : 9.61, CCI20 : 60.68, Chaikin Money Flow : 0.24, MACD : 5.36, Money Flow Index : 64.25, ROC : 6.50, RSI : 45.23, STOCH (14,3) : 54.24, STOCH RSI : 0.00, UO : 51.23, Williams %R : -45.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Illumina Inc. in the last 12-months were: Aimee L. Hoyt (Option Excercise at a value of $0), Aimee L. Hoyt (Sold 2 274 shares of value $798 250 ), Alexander Aravanis (Sold 12 404 shares of value $5 013 237 ), Charles E. Dadswell (Option Excercise at a value of $0), Charles E. Dadswell (Sold 3 202 shares of value $1 325 415 ), Francis A. DeSouza (Option Excercise at a value of $0), Joydeep Goswami (Option Excercise at a value of $0), Kevin Carl Pegels (Option Excercise at a value of $0), Phillip G. Febbo (Option Excercise at a value of $0), Phillip G. Febbo (Sold 2 988 shares of value $1 122 530 ), Sam A. Samad (Option Excercise at a value of $0), Susan H. Tousi (Option Excercise at a value of $0), Susan H. Tousi (Sold 2 250 shares of value $914 497 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (33.33 %)
3 (37.50 %)
3 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (55.56 %)
5 (62.50 %)
6 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (11.11 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.56
Moderate Buy
2.25
Moderate Buy
2.33

Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.

CEO: Francis A. DeSouza

Telephone: +1 858 202-4500

Address: 200 Illumina Way, San Diego 92122, CA, US

Number of employees: 7 850

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

61%39%

Bearish Bullish

61%39%

TipRanks News for ILMN

Fri, 22 Jul 2022 03:45 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Ionis Pharmaceuticals (IONS)

- TipRanks. All rights reserved.

Mon, 18 Jul 2022 03:16 GMT Illumina (ILMN) Gets a Hold Rating from SVB Securities

- TipRanks. All rights reserved.

Fri, 20 May 2022 01:10 GMT Illumina (ILMN) Receives a Hold from Credit Suisse

- TipRanks. All rights reserved.

Tue, 10 May 2022 12:05 GMT Analysts Offer Insights on Healthcare Companies: Heska (HSKA), Illumina (ILMN) and Owens & Minor (OMI)

- TipRanks. All rights reserved.

Sat, 07 May 2022 03:37 GMT Illumina (ILMN) Gets a Hold Rating from Robert W. Baird

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 09:07 GMT OTR Global Upgrades Illumina (ILMN) to Buy

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 01:10 GMT Illumina (ILMN) was Upgraded to a Hold Rating at Credit Suisse

- TipRanks. All rights reserved.

Thu, 06 Jan 2022 14:05 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN), Illumina (ILMN) and Catalent (CTLT)

- TipRanks. All rights reserved.

News

Stocktwits